CORT Corcept Therapeutics Inc

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

$25.44  +1.66 (6.98%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/14/2004
Outstanding shares:  106,250,716
Average volume:  723,982
Market cap:   $2,526,642,026
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      B00SCY1

---

Valuation   (See tab for details)

---

PE ratio:   24.17
PB ratio:   6.63
PS ratio:   6.65
Return on equity:   27.43%
Net income %:   29.41%